10 completed, 4 unknown, 3 recruiting, 2 active not recruiting. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 10, Unknown 4, Recruiting 3, Active not recruiting 2, Terminated 2, Withdrawn 1 |
Follow Rejection, Psychology: new trials by email Literature Review of Rejection, Psychology trials Research Report on Rejection, Psychology
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parenteral Ascorbic Acid Repletion in TransplantatIon Ascorbic acid, Placebo - Liver Transplant Failure and Rejection | Phase 4 | Withdrawn | University of Wisconsin, Madison | 2026-09-01 | 2026-09-18 | |
| Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids. - Kidney Transplantation | Phase 4 | Recruiting | University Hospital, Antwerp | 20 | 2024-08-20 | 2024-08-21 |
| Empagliflozin Treatment in Kidney Transplant Recipients Empagliflozin - Kidney Transplant, Chronic Kidney Disease | Phase 4 | Recruiting | VA Office of Research and Development | 264 | 2024-04-05 | 2026-04-21 |
| Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Grafalon, Normal Treatment - Kidney Transplant Failure and Rejection | Phase 4 | Active not recruiting | Fundación Canaria Instituto de Investigación Sanitaria de Canarias | 80 | 2022-07-05 | 2026-09-08 |
| Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) - Kidney Transplantation, Kidney Transplant Rejection | Phase 4 | Terminated | University of Southern California | 20 | 2021-11-23 | 2025-11-10 |
| Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients Basiliximab 20 milligram [Simulect], Normal Saline - Kidney Transplantation | Phase 4 | Unknown | King Faisal Specialist Hospital & Research Center | 140 | 2020-09-01 | 2021-02-18 |
| Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients Extended-release tacrolimus, Immediate-release tacrolimus - Kidney Transplant Rejection | Phase 4 | Completed | Cedars-Sinai Medical Center | 20 | 2020-01-09 | 2024-07-10 |
| Allograft Dysfunction in Heart Transplant Regadenoson - Heart Transplant Failure and Rejection | Phase 4 | Recruiting | Paul Kim | 376 | 2019-10-01 | 2026-05-01 |
| Envarsus XR® in Adolescent Renal Transplant Recipients Envarsus XR, Tacrolimus - Kidney Transplantation, Renal Transplantation | Phase 4 | Active not recruiting | University of California, Los Angeles | 28 | 2019-01-15 | 2023-02-09 |
| Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation Tacrolimus Extended Release Oral Tablet, Tacrolimus - Renal Transplant Rejection, Kidney Transplant Failure and Rejection | Phase 4 | Completed | Columbia University | 50 | 2018-07-26 | 2024-07-17 |
| Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients biomarkers driven immunosuppressive therapy - Kidney Transplant Failure and Rejection | Phase 4 | Unknown | ORIOL BESTARD | 164 | 2017-11-10 | 2021-01-08 |
| AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation ENVARSUS, Standard twice daily tacrolimus - Kidney Transplant Failure and Rejection | Phase 4 | Unknown | University Hospital Birmingham NHS Foundation Trust | 40 | 2017-04-01 | 2016-12-29 |
| Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients Belatacept, Tacrolimus, Mycophenolate - Implant or Graft; Rejection | Phase 4 | Completed | Columbia University | 57 | 2014-06-01 | 2021-02-10 |
| Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Thymoglobulin, Everolimus, Basiliximabe - Cytomegalovirus Infection, Renal Transplant Failure | Phase 4 | Completed | Hospital do Rim e Hipertensão | 300 | 2011-05-01 | 2015-03-23 |
| Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix) - Decreased Immunologic Activity [PE], Influenza | Phase 4 | Completed | Erasme University Hospital | 185 | 2009-10-01 | 2011-02-17 |
| Study of Glycemic Control on Liver Transplantation Outcomes Insulin - Evidence of Liver Transplantation, Hyperglycemia | Phase 4 | Completed | Northwestern University | 164 | 2009-04-01 | 2016-12-23 |
| Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation Tacrolimus (Kidney transplant maintenance immunosuppression), Kidney transplant maintenance immunosuppression - End-stage Renal Failure, Graft Rejection | Phase 4 | Completed | Imperial College Healthcare NHS Trust | 102 | 2008-12-01 | 2021-08-27 |
| Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Rabbit Antithymocyte Globulin, Velcade, Rituxan - Kidney Transplantation | Phase 4 | Completed | University of Cincinnati | 40 | 2008-09-01 | 2016-01-20 |
| Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients sirolimus (drug), mmf (drug) - Renal Transplantation | Phase 4 | Completed | University Hospital Muenster | 80 | 2005-06-01 | 2010-01-13 |
| A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression Tacrolimus (TAC), Sirolimus, Alemtuzumab - Kidney Transplant Failure and Rejection | Phase 4 | Terminated | Northwestern University | 40 | 2005-04-01 | 2015-10-26 |
Showing 20 of 22. Sign in to see all of them.
Cytomegalovirus Infections (2) · Coronary Disease (1) · Delayed Graft Function (1) · Diabetes Mellitus (1) · Hyperglycemia (1) · Hypoglycemia (1) · Influenza, Human (1) · Insulin Resistance (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Proteinuria (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Behavior (22) · Social Behavior (22) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Infections (3) · Male Urogenital Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Virus Diseases (3) · Chronic Disease (2) · DNA Virus Infections (2) · Disease Attributes (2) · Glucose Metabolism Disorders (2)
Tacrolimus (9) · Mycophenolic Acid (6) · Sirolimus (3) · Basiliximab (2) · Methylprednisolone (2) · thymoglobulin (2) · Abatacept (1) · Adrenal Cortex Hormones (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Ascorbic Acid (1) · Azathioprine (1) · Bortezomib (1) · Combined Modality Therapy (1) · Everolimus (1)
Columbia University (2) · Northwestern University (2) · Cedars-Sinai Medical Center (1) · Erasme University Hospital (1) · Fundación Canaria Instituto de Investigación Sanitaria de Canarias (1) · Hospital do Rim e Hipertensão (1) · Imperial College Healthcare NHS Trust (1) · King Faisal Specialist Hospital & Research Center (1) · Newark Beth Israel Medical Center (1) · ORIOL BESTARD (1) · Paul Kim (1) · Sociedad Andaluza de Trasplantes de Organos y Tejidos (1) · University Hospital Birmingham NHS Foundation Trust (1) · University Hospital Muenster (1) · University Hospital, Antwerp (1)
United States (12) · Spain (3) · Belgium (2) · Brazil (1) · Germany (1) · Saudi Arabia (1) · United Kingdom (1)
Adam G McLean, MA DPhil (1) · Adnan Sharif, MD (1) · Daniel Abramowicz, PhD (1) · David A Baran, MD (1) · E. Steve Woodle, MD (1) · Hans de Fijter, MD PhD (1) · Joseph R Leventhal, MD, PhD (1) · Mark A. Hardy, MD (1) · Mark E Molitch, M.D. (1) · Mark Hardy, MD (1) · Martin Hausberg, MD (1) · Miguel A Gonzalez Molina, MD (1) · Molly Groose, MD, MS (1) · Paul Kim, MD (1)
PMID 11693758, PMID 11943259, PMID 16890123, PMID 17919618, PMID 18551063, PMID 19284612, PMID 20413602, PMID 20643330, PMID 21216835, PMID 21555100, PMID 21962016, PMID 24355800, PMID 24457279, PMID 25988935, PMID 3308166, PMID 33988338, PMID 36094829, PMID 36344929, PMID 37526194
2008 (1)